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A B S T R A C T
Background. Depression is common in individuals with
chronic kidney disease (CKD). However, data on the association
of albuminuria, which together with reduced estimated glomer-
ular filtration rate (eGFR) defines CKD, with depression are
scarce and conflicting. In addition, it is not clear when in the
course from normal kidney function to CKD the association
with depression appears.
Methods. We examined the cross-sectional associations of albu-
minuria and eGFR with depressive symptoms and depressive
episodes in 2872 and 3083 40- to 75-year-old individuals,
respectively, who completed the baseline survey of an ongoing
population-based cohort study conducted in the southern part
of The Netherlands between November 2010 and September
2013. Urinary albumin excretion (UAE) was the average UAE
in two 24-h urine collections and eGFR was calculated with the
Chronic Kidney Disease Epidemiology Collaboration equation
based on creatinine and cystatin C. Depressive symptoms were
assessed with the 9-item Patient Health Questionnaire (PHQ-9)
and the presence of a minor or major depressive episode was
assessed with the MINI-International Neuropsychiatric
Interview.
Results. In total, 5.4% had a minor or major depressive episode.
UAE was <15 mg/24 h in 81.2%, 15–<30 mg/24 h in 10.3%
and 30 mg/24 h in 8.6%. In a multivariable logistic regression
analysis adjusted for potential confounders, and with UAE <15
mg/24 h as reference category, the odds ratio for a minor or
major depressive episode was 2.13 [95% confidence interval
(CI) 1.36–3.36] for UAE 15–<30 mg/24 h and 1.81 (95% CI
1.10–2.98) for UAE 30 mg/24 h. The average eGFR was 88.2
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6 14.7 mL/min/1.73 m2. eGFR was not associated with the
presence of a minor or major depressive episode. Results were
similar when we assessed associations with depressive symp-
toms or clinically relevant depressive symptoms (PHQ-9 score
10).
Conclusions. Albuminuria was associated with depressive
symptoms and depressive episodes, even at levels of UAE that
do not fulfil the CKD criteria. Future longitudinal studies should
examine the direction of this association and whether albumi-
nuria could serve as a biomarker to identify individuals at risk
of depression.
Keywords: albuminuria, depression, depressive symptoms,
estimated glomerular filtration rate, urinary albumin excretion
I N T R O D U C T I O N
Depression is common in individuals with chronic kidney dis-
ease (CKD) (prevalence 25%) [1], in whom it is associated
with increased morbidity [2] and mortality [3]. The frequent
occurrence of cerebral small vessel disease (cSVD) in CKD [4]
may be one explanation for the high prevalence of depression in
CKD. According to the vascular depression hypothesis [5, 6],
cSVD may lead to depression through disruption of neuronal
circuits involved in mood regulation. Furthermore, neurotoxic
effects of the uraemic milieu [7] and the presence of comorbid-
ities [8] such as obesity, type 2 diabetes mellitus (T2DM) and
hypertension may be involved.
However, data on the association of albuminuria, which
together with reduced estimated glomerular filtration rate
(eGFR) defines CKD [9], with depression are scarce and con-
flicting [10, 11]. Albuminuria may indicate generalized endo-
thelial dysfunction [12, 13], which in the brain may cause cSVD
[14]. Therefore, albuminuria may be a biomarker of vascular
disease processes involved in depression. Indeed, albuminuria
was borderline statistically significantly associated with depres-
sive symptoms in individuals with DM without cardiovascular
disease (CVD) [10]. In contrast, it was not associated in individ-
uals with DM with CVD [10] or in a CKD population [11].
However, in both studies, assessment of depressive symptoms
instead of a diagnosis of minor or major depressive episode may
have led to misclassification of somatic symptoms of (comor-
bid) disease as depressive symptoms [1].
In addition, it is not clear when in the course from normal
kidney function to CKD the associations of eGFR and albumi-
nuria with depression appear. Literature on the associations of
eGFR and albuminuria with CVD [15, 16] suggests that both
may already be associated with adverse health outcomes at lev-
els that do not fulfil the CKD criteria. In this regard, the results
of previous studies suggest that eGFR may not be associated
with depression until moderately to severely reduced [11, 17–
29], whereas data on this topic are lacking for albuminuria.
In view of the above, we examined whether albuminuria and
eGFR were, independent of each other, associated with both
self-reported depressive symptoms and an interview-based
diagnosis of minor or major depressive episode in a population-
based cohort without substantial CKD.
M A T E R I A L S A N D M E T H O D S
The Maastricht Study population and design
We used data from the Maastricht Study, an observational
prospective population-based cohort study [30]. Eligible for
participation were all individuals between 40 and 75 years of
age living in the southern part of The Netherlands. Recruitment
was stratified according to known T2DM, with an oversampling
of individuals with T2DM, for reasons of efficiency. The present
report includes cross-sectional data from the first 3451 partici-
pants, who completed the baseline survey between November
2010 and September 2013. The examinations of each partici-
pant were performed within a time window of 3 months. The
study was approved by the institutional medical ethical commit-
tee (NL31329.068.10) and the Minister of Health, Welfare and
Sports of the Netherlands (Permit 131 088-10 5234-PG) and
was conducted in accordance with the Declaration of Helsinki.
All participants gave written informed consent.
Kidney function
To assess urinary albumin excretion (UAE), participants were
requested to collect two 24-h urine collections (Supplemental
Methods). UAE was based on the average of two (available in 91.5%
of the participants) 24-h urine collections. GFR was estimated with
the Chronic Kidney Disease Epidemiology Collaboration equation
based on the combination of serum creatinine and serum cystatin C
(eGFRcrcys) (Supplemental Methods) [31].
Depressive symptoms
Depressive symptoms were assessed with a validated Dutch
version of the 9-item Patient Health Questionnaire (PHQ-9)
[32]. The PHQ-9 is a self-administered questionnaire based on
the Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV) criteria for a major depressive episode. It
comprises nine items rated on a 4-point scale, ranging from 0
(‘not at all’) to 3 (‘nearly every day’). Response options are used
to calculate a continuous total depressive symptom score rang-
ing from 0 (no symptoms) to 27 (all symptoms present nearly
every day). When one or two items were missing, the total score
was calculated as 9  (total points/9  number of missing
items) and rounded to the nearest integer. As a continuous vari-
able, scores 0–9 represent no, 10–14 represent moderate, 15–19
represent moderately severe and 20–27 represent severe depres-
sion [33]. A predefined cut-off score of 10 was considered to
indicate clinically relevant depressive symptoms [32].
In addition, we calculated affective (i.e. anhedonia, depressed
mood, feeling of worthlessness, thoughts of death) and somatic
(i.e. fatigue, appetite changes, sleep difficulties, concentration
difficulties, psychomotor agitation/retardation) subscores, based
on a confirmatory factor analysis conducted previously [34].
Minor and major depressive episode
The Mini-International Neuropsychiatric Interview (MINI)
[35] was used to assess the presence of a minor or major depres-
sive episode in the preceding 2 weeks according to the DSM-IV
criteria. A major depressive episode was diagnosed if participants
had at least one core symptom (i.e. depressed mood or
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|anhedonia) and at least four other symptoms of depression (i.e.
significant weight change or change in appetite, insomnia or
hypersomnia, psychomotor agitation or retardation, fatigue or
loss of energy, guilt or worthlessness, diminished ability to think
or concentrate or indecisiveness and suicidal thoughts or plans).
Persons suffering from one core symptom and one to three other
symptoms were classified as having a minor depressive episode.
Potential confounders
We assessed glucose metabolism status, body mass index,
waist circumference, total cholesterol, high-density lipoprotein
(HDL) cholesterol, low-density lipoprotein (LDL) cholesterol,
triglycerides, office blood pressure, 24-h average ambulatory
blood pressure, medication use, smoking behaviour, alcohol
consumption, prevalent CVD, educational level, marital status,
medical history, physical activity and cognitive performance, as
described previously [30, 36]. Glucose metabolism was classified
according to the World Health Organization 2006 criteria [37]
into normal glucose metabolism, impaired fasting glucose,
impaired glucose tolerance and DM. Participants with DM and
participants using glucose-lowering medication were consid-
ered as having T2DM if they had no (self-reported) type 1 or
other specific type of DM. For this study, impaired fasting glu-
cose and impaired glucose tolerance were combined into pre-
diabetes. Body mass index was calculated by dividing weight by
height2 and classified into normal weight (<25 kg/m2), over-
weight (25–<30 kg/m2) and obesity (30 kg/m2). The
total:HDL cholesterol ratio was calculated by dividing total cho-
lesterol by HDL cholesterol. Hypertension was defined as an
office systolic pressure140 mmHg, an office diastolic pressure
90 mmHg and/or the use of antihypertensive medication.
Smoking behaviour was classified into never, former and cur-
rent. Alcohol consumption was classified into no consumption,
low consumption (<7 glasses per week for women; <14 glasses
per week for men) and high consumption (>7 glasses per week
for women; >14 glasses per week for men). Prevalent CVD was
defined as a self-reported history of myocardial infarction, cere-
brovascular infarction or hemorrhage or percutaneous artery
angioplasty of or vascular surgery on the coronary, abdominal,
peripheral or carotid arteries. Educational level was classified
into low (none, primary, or lower vocational education only),
intermediate (intermediate general secondary, intermediate
vocational or higher general secondary education) and high
(higher vocational education or university level of education)
[38, 39]. Participants who were married or in a civil partnership
or who cohabited were classified as married/living with spouse.
Participants were classified as having comorbid disease other
than T2DM and CVD if they reported being diagnosed with
non-skin cancer, inflammatory bowel disease, inflammatory
respiratory disease and/or Parkinson’s disease (28 participants
with missing data were classified as having no comorbid dis-
ease). A modified version of the Community Healthy Activities
Model Program for Seniors (CHAMPS) questionnaire [40] was
used to assess weekly total and moderate to vigorous physical
activity. The Mini-Mental State Examination (MMSE) was used
as a measure of global cognitive performance [41]. In addition,
we assessed information processing speed as the standardized
composite score of the Stroop Color Word Test Parts I and II
[42], the Concept Shifting Test Parts A and B [43] and the
Letter-Digit Substitution Test [44], as this cognitive domain has
been associated with albuminuria in the present cohort [36].
Statistical analyses
All analyses were performed with SPSS Statistics Version
22.0 (IBM, Armonk, NY, USA) unless stated otherwise.
Population characteristics were presented stratified by the pres-
ence of clinically relevant depressive symptoms and by the pres-
ence of a major depressive episode. Associations of albuminuria
and eGFRcrcys with depressive symptoms were evaluated with
negative binomial regression analyses because of the extremely
skewed distribution of PHQ-9 scores [45] (Stata Statistical
Software, release 11.2SE; StataCorp, College Station, TX, USA).
Albuminuria was entered as a categorical variable [<15 mg/24
h (reference category), 15–<30 mg/24 h and 30 mg/24 h]
since the associations appeared to be nonlinear [46]. eGFRcrcys
was entered as a continuous variable and expressed per 10 mL/
min/1.73 m2 lower eGFRcrcys. The regression coefficients were
exponentiated to obtain the ratio of the depressive symptom
score per 10 mL/min/1.73 m2 lower eGFRcrcys or when com-
pared with UAE<15 mg/24 h.
Associations of albuminuria and eGFRcrcys with clinically
relevant depressive symptoms, major depressive episode and
minor or major depressive episode were evaluated with multi-
variable logistic regression analyses.
All regression analyses were adjusted for potential confound-
ers as follows: model 1: unadjusted model; model 2: age, sex, edu-
cational level, marital status, comorbid disease, glucose
metabolism status; model 3: model 2 þ waist circumference,
total:HDL cholesterol, triglycerides, the use of lipid-modifying
medication, smoking behaviour, alcohol consumption; model 4:
model 3þ eGFRcrcys or UAE; model 5a: model 4þ office systolic
pressure, the use of antihypertensive medication, prevalent CVD;
model 5b: model 5a but with replacement of office systolic pres-
sure by 24-h average ambulatory systolic pressure. Blood pressure
and prevalent CVD were added separately, as these variables may
be confounders and/or intermediates in the above associations.
Several additional analyses were performed to explore the
robustness of our results. First, we restricted the analyses to partici-
pants with UAE 300 mg/24 h and to the subpopulation with
two valid urine collections. Second, we additionally adjusted for
total or moderate to vigorous physical activity. Third, we addition-
ally adjusted for cognitive performance, expressed as either the
MMSE score or information processing speed. Fourth, we assessed
associations of albuminuria and eGFRcrcys with affective and
somatic subscores of the PHQ-9 to explore whether any associa-
tions with the total PHQ-9 score were driven by somatic com-
plaints in individuals with higher UAE or lower eGFRcrcys. Fifth,
we included antidepressant use in our definitions of major depres-
sive episode and minor or major depressive episode.
R E S U L T S
Characteristics of the study population
Figure 1 presents a flow diagram delineating the derivation of
the final study populations. The analyses on the PHQ-9 were
130 R.J.H. Martens et al.
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|based on 2872 participants (PHQ-9 subpopulation) and the anal-
yses on the MINI on 3083 participants (MINI subpopulation).
Table 1 shows the characteristics of the MINI subpopulation.
Due to oversampling, 846 (27.4%) participants had T2DM. In
total, 122 (4.3%) participants had clinically relevant depressive
symptoms, 112 (3.6%) had a major depressive episode and 54
(1.8%) had a minor depressive episode. Of those with a major
or minor depressive episode, 33 (29.5%) and 4 (7.4%) used an
antidepressant, respectively. Characteristics of the PHQ-9 sub-
population (Table 1) were similar.
In general, participants with a major depressive episode were
slightly younger, slightly more often women, less educated,
more often lived alone, more often had T2DM or other comor-
bid disease, had a worse CVD risk profile and had a lower infor-
mation processing speed.
Albuminuria, depressive symptoms and depressive
episodes
The median UAE was 6.7 [interquartile range (IQR) 4.0–
11.9] mg/24 h. UAE was <15 mg/24 h in 2502 (81.2%) partici-
pants, 15–<30 mg/24 h in 317 (10.3%) participants and 30
mg/24 h in 264 (8.6%) participants (Table 1).
The median depressive symptom score was 2 (IQR 0–4), 2
(IQR 0–5) and 2 (IQR 1–5) in individuals with UAE <15 mg/
24 h, 15–<30 mg/24 h and 30 mg/24 h, respectively. After
adjustment, and when compared with participants with UAE
<15 mg/24 h, participants with UAE 15–<30 mg/24 h and30
mg/24 h had a higher depressive symptom score and more often
had a depressive episode, regardless of their definitions
(Table 2, model 5a). That is, the odds ratio (OR) and for clini-
cally relevant depressive symptoms was 2.28 [95% confidence
interval (CI) 1.34–3.89] for UAE 15–<30 mg/24 h and 1.84
(95% CI 1.00–3.35) for UAE 30 mg/24 h (Table 2, model 5a).
Similarly, the OR for a major depressive episode was 2.49 (95%
CI 1.48–4.21) for UAE 15–<30 mg/24 h and 1.76 (95% CI
0.97–3.21) for UAE 30 mg/24 h (Table 2, model 5a). In addi-
tion, the OR for minor or major depressive episode was 2.13
(95% CI 1.36–3.36) for UAE 15–<30 mg/24 h and 1.81 (95% CI
1.10–2.98) for UAE30 mg/24 h (Table 2, model 5a).
When the above associations were adjusted for 24-h average
ambulatory systolic pressure the instead of office systolic pres-
sure, the results were similar (Table 2, model 5b).
eGFR, depressive symptoms and depressive episodes
The average eGFRcrcys was 88.2 6 14.7 mL/min/1.73 m
2
(Table 1). eGFRcrcys was 90 mL/min/1.73 m2 in 1497 (48.6%)
participants, 60–<90 mL/min/1.73 m2 in 1461 (47.4%) partici-
pants and<60 mL/min/1.73 m2 in 125 (4.1%) participants.
The median depressive symptom score was 2 (IQR 0–5), 1.5
(IQR 0–4) and 2 (IQR 0–4) for individuals with eGFRcrcys <60
mL/min/1.73 m2, 60–<90 mL/min/1.73 m2 and 90 mL/min/
1.73 m2, respectively.
FIGURE 1: Flow diagram delineating the derivation of the final study populations. eGFRcrcys, estimated glomerular filtration rate based on cre-
atinine and cystatin C; CVD, cardiovascular disease; MINI, MINI-International Neuropsychiatric Interview; PHQ-9, Patient Health
Questionnaire-9. *Missing data were not mutually exclusive.
K i d n e y f u n c t i o n a n d d e p r e s s i o n 131
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article/33/1/128/2676211 by U
niversiteit M
aastricht user on 03 N
ovem
ber 2020
Table 1. Characteristics of the study population and stratified by the presence of clinically relevant depressive symptoms and by the presence of a major
depressive episode
Study
populationa
Clinically relevant depressive
symptoms (PHQ-9)a
Major depressive
episode (MINI)a
No (n ¼ 2749) Yes (n ¼ 123) P-valuec No (n ¼ 2971) Yes (n ¼ 112) P-valuec
Demographics
Age (years) 59.8 6 8.2 59.8 6 8.2 55.9 6 7.8 <0.001 59.8 6 8.2 58.4 6 8.4 0.07
Men 1596 (51.8) 1423 (51.8) 50 (40.7) 0.02 1542 (51.9) 54 (48.2) 0.44
Married/living with spouse 2482 (80.5) 2250 (81.8) 77 (62.6) <0.001 2405 (80.9) 77 (68.8) 0.001
Educational level <0.001 <0.001
Low 508 (16.5) 406 (14.8) 33 (26.8) 472 (15.9) 36 (32.1)
Intermediate 1323 (42.9) 1194 (43.4) 57 (46.3) 1271 (42.8) 52 (46.4)
High 1252 (40.6) 1149 (41.8) 33 (26.8) 1228 (41.3) 24 (21.4)
Lifestyle variables
Smoking behaviour <0.001 <0.001
Never smoker 1078 (35.0) 987 (35.9) 28 (22.8) 1055 (35.5) 23 (20.5)
Former smoker 1598 (51.8) 1425 (51.8) 58 (47.2) 1541 (51.9) 57 (50.9)
Current smoker 407 (13.2) 337 (12.3) 37 (30.1) 375 (12.6) 32 (28.6)
Alcohol consumption <0.001 <0.001
None 563 (18.3) 462 (16.8) 44 (35.8) 521 (17.5) 42 (37.5)
Low (women 7 glasses/week;
men 14 glasses/week)
1707 (55.4) 1550 (56.4) 55 (44.7) 1659 (55.8) 48 (42.9)
High (women >7 glasses/week;
men >14 glasses/week)
813 (26.4) 737 (26.8) 24 (19.5) 791 (26.6) 22 (19.6)
Total physical activity (h/week)b 13.0 (8.3–18.5) 13.0 (8.3–18.5) 11.5 (6.0–19.8) 0.08 13.0 (8.3–18.8) 11.0 (6.0–16.9) 0.006
Moderate to vigorous physical
activity (h/week)b
4.5 (2.3–8.0) 4.5 (2.3–8.0) 3.0 (0.8–6.7) <0.001 4.5 (2.3–8.0) 3.0 (0.8–5.9) <0.001
Clinical characteristics
BMI categoriesb 0.001 <0.001
Normal weight (<25 kg/m2) 1074 (34.8) 989 (36.0) 29 (23.6) 1051 (35.4) 23 (20.5)
Overweight (25–30 kg/m2) 1322 (42.9) 1179 (42.9) 52 (42.3) 1274 (42.9) 48 (42.9)
Obesity (30 kg/m2) 686 (22.3) 581 (21.1) 42 (34.1) 645 (21.7) 41 (36.6)
Waist circumference (cm)
Men 101.4 6 11.9 100.9 6 11.5 107.0 6 15.8 0.01 101.2 6 11.7 106.8 6 13.9
Women 90.0 6 12.9 89.4 6 12.5 97.7 6 18.3 <0.001 89.8 6 12.7 96.4 6 16.6
Office systolic pressure (mmHg) 135.0 6 18.2 134.9 6 18.2 134.2 6 16.6 0.69 135.0 6 18.2 135.6 6 18.3 0.71
Office diastolic pressure (mmHg) 76.3 6 9.9 76.3 6 9.9 77.5 6 10.6 0.18 76.2 6 9.9 77.2 6 11.2 0.39
24 h average ambulatory systolic
pressure (mmHg)b
119.1 6 11.7 118.9 6 11.8 120.3 6 12.2 0.22 119.0 6 11.6 120.9 6 14.5 0.21
24 h average ambulatory diastolic
pressure (mmHg)b
73.5 6 7.2 73.5 6 7.2 75.4 6 8.0 0.007 73.5 6 7.1 75.5 6 9.0 0.03
Hypertension 1728 (56.0) 1519 (55.3) 75 (61.0) 0.21 1658 (55.8) 70 (62.5) 0.16
Glucose metabolism status 0.001 <0.001
Normal glucose metabolism 1761 (57.1) 1618 (58.9) 56 (45.5) 1715 (57.7) 46 (41.1)
Impaired fasting glucose 132 (4.3) 118 (4.3) 2 (1.6) 130 (4.4) 2 (1.8)
Impaired glucose tolerance 344 (11.2) 314 (11.4) 15 (12.2) 333 (11.2) 11 (9.8)
T2DM 846 (27.4) 699 (25.4) 50 (40.7) 793 (26.7) 53 (47.3)
Total cholesterol (mmol/l) 5.2 6 1.2 5.3 6 1.2 5.2 6 1.2 0.36 5.2 6 1.2 5.1 6 1.1 0.35
HDL cholesterol (mmol/l)
Men 1.3 6 0.4 1.3 6 0.4 1.3 6 0.4 0.14 1.3 6 0.4 1.2 6 0.3
Women 1.7 6 0.5 1.8 6 0.5 1.6 6 0.5 0.006 1.7 6 0.5 1.5 6 0.5
LDL cholesterol (mmol/l) 3.1 6 1.0 3.1 6 1.0 3.0 6 1.1 0.11 3.1 6 1.0 3.0 6 1.1 0.54
Triglycerides (mmol/l) 1.21 (0.88–1.72) 1.20 (0.87–1.70) 1.49 (1.05–2.18) <0.001 1.20 (0.88–1.70) 1.49 (1.02–2.13) <0.001
Total:HDL cholesterol ratio 3.7 6 1.2 3.7 6 1.2 3.9 6 1.5 0.12 3.7 6 1.2 4.0 6 1.4 0.005
Prevalent cardiovascular disease 509 (16.5) 434 (15.8) 28 (22.8) 0.04 482 (16.2) 27 (24.1) 0.03
Comorbidity 488 (15.8) 407 (14.8) 34 (27.6) <0.001 460 (15.5) 28 (25.0) 0.007
Kidney function
eGFRcrcys (ml/min/1.73 m
2) 88.2 6 14.7 88.2 6 14.6 90.2 6 14.8 0.14 88.2 6 14.7 87.4 6 15.6 0.57
eGFRcrcys categories 0.17 0.74
90 mL/min/1.73 m2 1497 (48.6) 1335 (48.6) 69 (56.1) 1445 (48.6) 52 (46.4)
60–<90 mL/min/1.73 m2 1461 (47.4) 1310 (47.7) 48 (39.0) 1407 (47.4) 54 (48.2)
<60 mL/min/1.73 m2 125 (4.1) 104 (3.8) 6 (4.9) 119 (4.0) 6 (5.4)
Urinary albumin excretion rate (mg/24 h) 6.7 (4.0–11.9) 6.5 (4.0–11.5) 7.8 (4.2–21.6) 0.007 6.6 (4.0–11.6) 8.8 (4.1–21.4) 0.004
Urinary albumin excretion categories <0.001 <0.001
<15 mg/24 h 2502 (81.2) 2258 (82.1) 81 (65.9) 2432 (81.9) 70 (62.5)
Continued
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|After adjustment, eGFRcrcys was not associated with the
depressive symptom score or the presence of a depressive epi-
sode, regardless of their definitions (Table 3, models 5a and 5b).
Additional analyses
Results were not materially altered when the analyses were
restricted to individuals with UAE 300 mg/24 h or to
Table1. Continued
Study
populationa
Clinically relevant depressive
symptoms (PHQ-9)a
Major depressive
episode (MINI)a
No (n ¼ 2749) Yes (n ¼ 123) P-valuec No (n ¼ 2971) Yes (n ¼ 112) P-valuec
15–<30 mg/24 h 317 (10.3) 272 (9.9) 22 (17.9) 294 (9.9) 23 (20.5)
30 mg/24 h 264 (8.6) 219 (8.0) 20 (16.3) 245 (8.2) 19 (17.0)
Medication
Antihypertensive medication 1214 (39.4) 1052 (38.3) 60 (48.8) 0.02 1157 (38.9) 57 (50.9) 0.01
Renin–angiotensin system inhibitor 915 (29.7) 790 (28.7) 45 (36.6) 0.06 869 (29.2) 46 (41.1) 0.007
Lipid-modifying medication 1092 (35.4) 940 (34.2) 51 (41.5) 0.10 1044 (35.1) 48 (42.9) 0.09
Antidepressant medication 205 (6.6) 149 (5.4) 35 (28.5) <0.001 172 (5.8) 33 (29.5) <0.001
Mental health and cognitive performance
PHQ-9 scoreb 2 (0–4) 2 (0–4) 12 (11–16) <0.001 2 (0–4) 10 (7–16) <0.001
Clinically relevant depressive
symptoms (PHQ-9  10)b
122 (4.3) – – – 75 (2.7) 47 (51.6) <0.001
Major depressive episode 112 (3.6) 44 (1.6) 47 (38.5) <0.001 – – –
Minor or major depressive episode 166 (5.4) 81 (3.0) 57 (46.7) <0.001 – – –
MMSE scoreb 29 (28–30) 29 (28–30) 29 (28–30) 0.01 29 (28–30) 29 (28–30) <0.001
Information processing speedb 0.00 6 1.00 0.01 6 0.98 0.16 6 1.20 0.13 0.02 6 0.99 0.41 6 1.19 <0.001
Data are presented as n (%), mean 6 SD or median (IQR). BMI, body mass index.
aThe columns ‘Study population’ and ‘Major depressive episode (MINI)’ present the characteristics of the MINI subpopulation (n ¼ 3083), whereas the column ‘Clinically relevant
depressive symptoms (PHQ-9)’ presents the characteristics of the PHQ-9 subpopulation (n ¼ 2872).
bFor the MINI subpopulation available in n ¼ 2704 (total physical activity), n ¼ 2703 (moderate to vigorous physical activity), n ¼ 3082 participants (BMI categories), n ¼ 2731 partic-
ipants (24 h average ambulatory systolic and diastolic pressure), n ¼ 2842 (PHQ-9 score), n ¼ 2842 (clinically relevant depressive symptoms (PHQ-9  10)), n ¼ 3081 (MMSE score)
and n ¼ 3029 (information processing speed) participants. For the PHQ-9 subpopulation available in n ¼ 2686 (total physical activity), n ¼ 2685 (moderate to vigorous physical activ-
ity), n ¼ 2871 (BMI categories), n ¼ 2559 (24 h average ambulatory systolic and diastolic pressure), n ¼ 2842 (major depressive episode and major or minor depressive episode), n ¼
2865 (MMSE score) and n ¼ 2818 (information processing speed) participants.
cP-values for the comparison of participants with and without clinically relevant depressive symptoms and of participants with and without a major depressive episode were calculated
with the independent Student t-test for normally distributed variables, the Mann–Whitney U test for non-normally distributed variables and the v2 test for categorical variables.
Table 2. Associations of albuminuria with depressive symptoms and depressive episodes
PHQ-9 Clinically relevant
depressive symptoms
(PHQ-9 10)
Major depressive
episode
Minor or major
depressive episode
Model UAE Ratio (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
1 <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.34 (1.16–1.54) <0.001 2.26 (1.38–3.67) 0.001 2.72 (1.67–4.42) <0.001 2.32 (1.52–3.54) <0.001
30 mg/24 h 1.43 (1.23–1.67) <0.001 2.55 (1.53–4.23) <0.001 2.69 (1.60–4.55) <0.001 2.63 (1.70–4.07) <0.001
2 <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.38 (1.20–1.58) <0.001 2.45 (1.46–4.12) 0.001 2.64 (1.58–4.40) <0.001 2.24 (1.44–3.50) <0.001
30 mg/24 h 1.42 (1.22–1.66) <0.001 2.36 (1.33–4.17) 0.003 2.11 (1.19–3.73) 0.01 2.11 (1.31–3.40) 0.002
3 <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.33 (1.16–1.52) <0.001 2.31 (1.35–3.92) 0.002 2.47 (1.47–4.17) 0.001 2.14 (1.36–3.36) 0.001
30 mg/24 h 1.30 (1.12–1.52) 0.001 1.90 (1.05–3.44) 0.04 1.82 (1.01–3.30) 0.05 1.87 (1.14–3.07) 0.01
4 <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.32 (1.15–1.52) <0.001 2.30 (1.35–3.92) 0.002 2.49 (1.48–4.20) 0.001 2.14 (1.36–3.37) 0.001
30 mg/24 h 1.31 (1.12–1.53) 0.001 1.90 (1.05–3.45) 0.04 1.80 (0.99–3.27) 0.05 1.86 (1.13–3.05) 0.01
5a <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.32 (1.15–1.51) <0.001 2.28 (1.34–3.89) 0.003 2.49 (1.48–4.21) 0.001 2.13 (1.36–3.36) 0.001
30 mg/24 h 1.29 (1.10–1.50) 0.02 1.84 (1.00–3.35) 0.05 1.76 (0.97–3.21) 0.06 1.81 (1.10–2.98) 0.02
5b <15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.39 (1.20–1.61) <0.001 2.45 (1.36–4.39) 0.003 3.24 (1.83–5.72) <0.001 2.60 (1.61–4.20) <0.001
30 mg/24 h 1.30 (1.10–1.54) 0.002 1.86 (0.95–3.65) 0.07 1.73 (0.85–3.51) 0.13 1.83 (1.04–3.20) 0.04
Ratios represent the ratio of the depressive symptom score when compared with participants with UAE <15 mg/24 h. ORs represent the odds of having clinically relevant depressive
symptoms, a major depressive episode and a minor or major depressive episode, respectively, relative to the odds in participants with UAE <15 mg/24 h. Model 1: unadjusted model;
model 2: model 1 þ age, sex, educational level, marital status, comorbid disease, glucose metabolism status; model 3: model 2 þ waist circumference, total:HDL cholesterol ratio, trigly-
cerides, the use of lipid-modifying medication, smoking behaviour, alcohol consumption; model 4: model 3 þ eGFRcrcys; model 5a: model 4 þ office systolic pressure, the use of antihy-
pertensive medication, prevalent cardiovascular disease; model 5b: similar to model 5a but adjusted for ambulatory systolic pressure instead of office systolic pressure (missing in n ¼
313 participants for PHQ-9 and n ¼ 352 for major depressive episode and minor or major depressive episode).
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individuals with two valid urine collections (Table 4) or when
results were additionally adjusted for total or moderate to vigo-
rous physical activity, the MMSE score or information process-
ing speed (Tables 4 and 5). Analyses of the associations of
albuminuria and eGFRcrcys with somatic and affective subscores
of the PHQ-9 showed that albuminuria was associated with
both a higher affective and somatic symptom score, although
the association of UAE 30 mg/24 h with affective symptoms
was not statistically significant after adjustment for lifestyle fac-
tors and CVD risk factors. eGFRcrcys was associated with neither
subscore (data not shown). When we included antidepressant
use in our definition of major depressive episode and minor or
major depressive episode, UAE 15–<30 mg/24 h and 30 mg/
24 h remained associated with both major depressive episode
and minor or major depressive episode, although the strength
of the associations was attenuated and the association of UAE
30 mg/24 h with major depressive episode was no longer stat-
istically significant after adjustment for lifestyle factors and
CVD risk factors. eGFRcrcys was not associated with the alterna-
tive definitions of depressive episode (data not shown).
Table 3. Associations of eGFRcrcys with depressive symptoms and depressive episodes
PHQ-9 score Clinically relevant depressive
symptoms (PHQ-9 10)
Major depressive episode Minor or major
depressive episode
Model Ratio (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
1 0.98 (0.95; 1.01) 0.23 0.91 (0.80; 1.03) 0.14 1.04 (0.91; 1.18) 0.57 1.04 (0.94; 1.15) 0.47
2 1.02 (0.99; 1.05) 0.29 1.06 (0.92; 1.22) 0.44 1.08 (0.94; 1.24) 0.28 1.07 (0.95; 1.20) 0.27
3 0.99 (0.96; 1.03) 0.62 0.99 (0.86; 1.15) 0.90 1.03 (0.89; 1.18) 0.73 1.02 (0.90; 1.15) 0.77
4 0.99 (0.95; 1.02) 0.48 1.00 (0.86; 1.15) 0.95 1.03 (0.89; 1.19) 0.68 1.02 (0.90; 1.15) 0.78
5a 0.98 (0.95; 1.02) 0.29 0.99 (0.86; 1.15) 0.91 1.03 (0.89; 1.18) 0.73 1.01 (0.90; 1.14) 0.85
5b 0.99 (0.95; 1.02) 0.48 1.04 (0.88; 1.21) 0.67 1.05 (0.90; 1.24) 0.52 1.04 (0.91; 1.18) 0.58
Ratios represent the ratio of the depressive symptom score per 10 mL/min/1.73 m2 lower eGFR. ORs represent the relative difference in the odds of having clinically relevant depressive
symptoms, a major depressive episode and a minor or major depressive episode, respectively, per 10 mL/min/1.73 m2 lower eGFR. Model 1: unadjusted model; model 2: model 1 þ age,
sex, educational level, marital status, comorbid disease, glucose metabolism status; model 3: model 2 þ waist circumference, total:HDL cholesterol ratio, triglycerides, the use of lipid-
modifying medication, smoking behavior, alcohol consumption; model 4: model 3 þ UAE (categorical); model 5a: model 4 þ office systolic pressure, the use of antihypertensive medi-
cation, prevalent cardiovascular disease; model 5b: similar to model 5a but adjusted for ambulatory systolic pressure instead of office systolic pressure (missing in n ¼ 313 participants
for PHQ-9 and n ¼ 352 for major depressive episode and minor or major depressive episode).
Table 4. Additional analyses of the associations of albuminuria with depressive symptoms and depressive episodes
PHQ-9 Clinically relevant depressive
symptoms (PHQ-9  10)
Major depressive episode Minor or major
depressive episode
UAE Ratio (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Model 5a þ total physical activity (n ¼ 2686 for PHQ-9; n ¼ 2704 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.33 (1.16–1.53) <0.001 2.35 (1.33–4.15) 0.003 3.09 (1.74–5.49) <0.001 2.71 (1.66–4.42) <0.001
30 mg/24 h 1.30 (1.10–1.53) 0.002 2.10 (1.09–4.02) 0.03 1.32 (0.60–2.90) 0.49 1.69 (0.92–3.11) 0.09
Model 5a þ moderate to vigorous physical activity (n ¼ 2685 for PHQ-9; n ¼ 2703 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.33 (1.16–1.53) <0.001 2.35 (1.33–4.15) 0.003 3.08 (1.73–5.46) <0.001 2.70 (1.66–4.40) <0.001
30 mg/24 h 1.30 (1.10–1.53) 0.002 2.09 (1.09–4.01) 0.03 1.32 (0.60–2.88) 0.49 1.68 (0.92–3.08) 0.09
Model 5a þMMSE (n ¼ 2865 for PHQ-9; n ¼ 3081 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.32 (1.15–1.52) <0.001 2.33 (1.36–3.98) 0.002 2.51 (1.48–4.23) 0.001 2.15 (1.37–3.39) 0.001
30 mg/24 h 1.29 (1.11–1.51) 0.001 1.92 (1.05–3.52) 0.03 1.77 (0.97–3.23) 0.06 1.81 (1.10–3.00) 0.02
Model 5a þ information processing speed (n ¼ 2818 for PHQ-9; n ¼ 3029 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.31 (1.15–1.52) <0.001 2.41 (1.40–4.13) 0.001 2.55 (1.50–4.33) 0.001 2.16 (1.37–3.42) 0.001
30 mg/24 h 1.27 (1.09–1.49) 0.003 2.07 (1.12–3.80) 0.02 1.69 (0.91–3.13) 0.10 1.75 (1.05–2.92) 0.03
Model 5a in subpopulation with UAE  300 mg/24 h (n ¼ 2852 for PHQ-9; n ¼ 3061 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.32 (1.15–1.52) <0.001 2.26 (1.33–3.86) 0.003 2.50 (1.48–4.22) 0.001 2.14 (1.36–3.37) 0.001
30 mg/24 h 1.30 (1.11–1.54) 0.001 1.96 (1.06–3.61) 0.03 1.84 (1.00–3.39) 0.05 1.92 (1.16–3.19) 0.01
Model 5a in individuals who collected two 24-h urine collections (n ¼ 2645 for PHQ-9; n ¼ 2821 for major and minor or major depressive episode)
<15 mg/24 h Reference Reference Reference Reference
15–<30 mg/24 h 1.23 (1.07–1.42) 0.005 2.04 (1.13–3.70) 0.02 1.84 (1.00–3.36) 0.05 1.76 (1.06–2.91) 0.03
30 mg/24 h 1.31 (1.11–1.54) 0.001 1.88 (0.98–3.59) 0.06 1.82 (0.97–3.42) 0.06 1.92 (1.14–3.22) 0.01
Ratios represent the ratio of the depressive symptom score when compared with participants with UAE <15 mg/24 h. ORs represent the odds of having clinically relevant depressive
symptoms, a major depressive episode, and a minor or major depressive episode, respectively, relative to the odds in participants with UAE <15 mg/24 h. Model 5a: age, sex, educa-
tional level, marital status, comorbid disease, glucose metabolism status, waist circumference, total:HDL cholesterol ratio, triglycerides, the use of lipid-modifying medication, smoking
behavior, alcohol consumption, eGFRcrcys, office systolic pressure, the use of antihypertensive medication, prevalent cardiovascular disease.
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||D I S C U S S I O N
To our knowledge, this study is the first to examine whether
albuminuria and eGFR are, independent of each other, associ-
ated with depression in a population-based setting. It had two
main findings. First, albuminuria was associated with both self-
reported depressive symptoms and minor or major depressive
episode after adjustment for demographic variables, comorbid-
ity, lifestyle factors and CVD risk factors (including eGFR),
even at levels of UAE that do not fulfil the CKD criteria.
Second, eGFR was neither associated with depressive symptoms
nor with minor or major depressive episode in this cohort with-
out substantial CKD.
The results of this study contrast with a study in individuals
with CKD [11], which showed no independent association
between albuminuria and depressive symptoms. However, its
participants were selected for the presence of CKD based on
eGFR values [11], whereas most participants in the present
population-based study had normal or mildly reduced eGFR.
The higher burden of symptoms of CKD and comorbid disease
[11] may have reduced the contrast between participants with
higher and lower albuminuria levels. In another study, albumi-
nuria was only borderline statistically significantly associated
with depressive symptoms in individuals with DM without
CVD but not with CVD [10]. However, a large proportion had
poor glycaemic control, and its complications may have been
classified erroneously as depressive symptoms.
Generalized endothelial dysfunction may explain the associ-
ation between albuminuria and depression. According to this
concept, microvascular endothelial dysfunction in the kidney
causes albuminuria [12, 13], whereas in the brain it causes
cSVD [14]. According to the vascular depression hypothesis [5,
6], the latter may lead to depression through disruption of neu-
ronal circuits involved in mood regulation in fronto-limbic
brain areas [5, 6]. Indeed, albuminuria has been associated with
magnetic resonance imaging findings of cSVD [47] and cSVD
has been associated with incident depressive symptoms [48, 49].
In addition, studies showing an association of (plasma) bio-
markers of endothelial dysfunction with depressive symptoms
[50] and minor or major depressive episode [51] indirectly sup-
port this view. However, we cannot rule out reverse causation.
Indeed, depressive symptoms [52] and major depressive episode
[2, 53] have been associated with a higher risk of end-stage renal
disease [2, 52, 53]. This may also be true for albuminuria, e.g.
through the adoption of an unhealthy lifestyle and poor treat-
ment adherence [54, 55]. However, adiposity, smoking behav-
ior, alcohol consumption and physical activity did not explain
the reported associations.
The non-linear association of albuminuria with depression
contrasts with the reported linear associations of (plasma) bio-
markers of endothelial dysfunction with depressive symptoms
[50] and minor or major depressive episode [51]. Selective non-
participation of individuals with depression and UAE 30 mg/
24 h due to a higher comorbid disease burden in these individu-
als [46, 56] (i.e. incidence–prevalence bias [57]) could account
for the non-linearity. Furthermore, the small number of cases
with depression limited power and the 95% CIs do not exclude
a linear association.
Importantly, the association of albuminuria with depression
is not likely due to misclassification of somatic symptoms of
comorbid disease, as albuminuria was associated with both self-
reported depressive symptoms and an interview-based diagno-
sis of minor or major depressive episode. Furthermore, we
adjusted for comorbid disease and albuminuria was related to
affective as well as somatic depressive symptoms.
A lack of power probably explains why the association of
UAE 30 mg/24 h with major depressive episode was border-
line statistically significant, whereas it was statistically signifi-
cant for minor and major depressive episode combined. Minor
and major depressive episodes are part of a continuum of mood
disorders, differing only in the number of depressive symptoms
[58]. Indeed, lower quality of life, more disability, higher health
care consumption and, although not consistently, increased
mortality in individuals with a minor depressive episode [58]
point to its clinical importance.
In contrast, the inclusion of individuals who only had an
early onset major depressive episode may have attenuated the
association between albuminuria and depression when antide-
pressant use was included in our definition of depression. Early
Table 5. Additional analyses of the associations of eGFRcrcys with depressive symptoms and depressive episodes
PHQ-9 Clinically relevant depressive
symptoms (PHQ-9  10)
Major depressive episode Minor or major
depressive episode
Ratio (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Model 5a þ total physical activity (n ¼ 2686 for PHQ-9; n ¼ 2704 for major and minor or major depressive episode)
0.97 (0.94–1.00) 0.08 1.00 (0.86–1.16) 0.98 0.98 (0.82–1.16) 0.79 0.99 (0.86–1.14) 0.90
Model 5a þ moderate to vigorous physical activity (n ¼ 2685 for PHQ-9; n ¼ 2703 for major and minor or major depressive episode)
0.97 (0.93–1.00) 0.06 0.99 (0.85–1.16) 0.93 0.97 (0.82–1.15) 0.74 0.99 (0.86–1.13) 0.84
Model 5a þMMSE (n ¼ 2865 for PHQ-9; n ¼ 3081 for major and minor or major depressive episode)
0.98 (0.95–1.02) 0.31 0.99 (0.85–1.14) 0.85 1.02 (0.89–1.18) 0.78 1.01 (0.89–1.14) 0.91
Model 5a þ information processing speed (n ¼ 2818 for PHQ-9; n ¼ 3029 for major and minor or major depressive episode)
0.98 (0.95–1.01) 0.24 0.98 (0.84–1.14) 0.77 1.01 (0.87–1.17) 0.93 1.00 (0.89–1.13) 0.99
Ratios represent the ratio of the depressive symptom score per 10 mL/min/1.73 m2 eGFRcrcys. ORs represent the relative difference in the odds of having clinically relevant depressive
symptoms, a major depressive episode, and a minor or major depressive episode, respectively, per 10 mL/min/1.73 m2 lower eGFRcrcys. Model 5a: age, sex, educational level, marital sta-
tus, comorbid disease, glucose metabolism status, waist circumference, total:HDL cholesterol ratio, triglycerides, the use of lipid-modifying medication, smoking behavior, alcohol con-
sumption, UAE (categorical), office systolic pressure, the use of antihypertensive medication, prevalent cardiovascular disease.
K i d n e y f u n c t i o n a n d d e p r e s s i o n 135
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article/33/1/128/2676211 by U
niversiteit M
aastricht user on 03 N
ovem
ber 2020
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
||
|and late-onset depression may have different causes [59] and
cerebrovascular disease is more likely involved in late-onset
depression [60]. In addition, antidepressants may have been
prescribed for indications other than depression, e.g. neuro-
pathic pain, leading to misclassification of depression status.
In this study without substantial CKD, eGFR was not associ-
ated with depression. However, this study was underpowered to
comment on the association of eGFR <60 mL/min/1.73 m2
with depression. Nevertheless, when combined with the results
of other studies on the association of eGFR with depression [11,
17–29], eGFR seems not to be associated with depression until
it is moderately toseverely reduced.
An important strength of this study was the assessment of
albuminuria with 24-h urine collections and the assessment of
eGFR based on creatinine and cystatin C. Another strength was
the evaluation of an interview-based diagnosis of DSM-IV
minor or major depressive episode, which reduced the risk of
misclassification of symptoms of somatic diseases as depressive
symptoms [1]. In addition, the elaborate clinical characteriza-
tion of the study participants allowed for extensive adjustment
for potential confounders, including 24-h average ambulatory
blood pressure. However, some limitations of this study should
be considered. First, the cross-sectional design limited causal
inferences. Second, even though we adjusted for an extensive
series of potential confounders, we cannot fully exclude residual
confounding. For example, we had no data on polymorphisms
of the renin–angiotensin system [60, 61] or activity of the hypo-
thalamic–pituitary–adrenal axis [62, 63]. Third, the exclusion of
participants with missing data may have led to an underestima-
tion of the examined associations if those with a higher UAE or
reduced eGFR and concomitant (severe) depression were selec-
tively excluded. Fourth, we had no data on the use of non-
pharmacological treatments of depression, which may have
been applied successfully in some participants and could have
led to an underestimation of the association of eGFR and albu-
minuria with depression. Fifth, the study population was
recruited from a single region in The Netherlands and primarily
consisted of Caucasian individuals of European descent
(98.6%), which may limit generalizability to other ethnic and
racial groups.
In conclusion, albuminuria was associated with depressive
symptoms and minor or major depressive episode, even at levels
of UAE that do not fulfil the CKD criteria. Future longitudinal
studies should examine the direction of this association and
whether albuminuria could serve as a biomarker to identify
individuals at risk of depression.
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A B S T R A C T
Background. The clinical and pathologic manifestations of
nephropathy due to type 2 diabetes are diverse, but large-scale
pathologic studies with long-term observations are limited.
Methods. Kidney biopsies and clinical data of 600 patients with
type 2 diabetes were collected retrospectively from 13 centres
across Japan. Thirteen pathologic findings (nine glomerular le-
sions, two interstitial lesions and two vascular lesions) were
clearly defined and scored.
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